- Theratechnologies (TH) shares data on Tregarzo at AIDS 2022 showing potential for improved treatment regimens
- New sub-analysis on Trogarzo clinical trial patients show long-term viral suppression is not influenced by partially active agents
- Predictive pharmacokinetic modelling shows that new methods of administration could provide similar kinetics to intravenous infusion
- Additional data highlights synergistic activities between Trogarzo and dolutegravir, etravirine, tenofovir alafenamide and lenacapavir, a long-acting investigational antiretroviral therapy (ARV)
- Theratechnologies (TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs
- Theratechnologies (TH) is up today, trading at C$2.86 as of Jul 28, 2:34 p.m. EDT
Theratechnologies (TH) share data on Tregarzo at AIDS 2022 showing potential for improved treatment regimens.
The information was from two presentations at the International AIDS Conference, held in Montreal from Jul 29th-Aug 2nd. The new data provide key understandings of the potential of Trogarzo (ibalizumab) to evolve treatment paradigms for heavily treatment-experienced HIV populations on complex regimens.
Dr. Jason Leider, Professor of Medicine at Albert Einstein College of Medicine says:
“Our sub-analysis showed that the combination of the fully active ARVs with ibalizumab most influenced virologic control with or without the partially active ARVs in combination. We know that complex resistance profiles often limit the number of fully active agents available. These results demonstrate our focus should be on utilizing all available fully active agents, which could lead to simpler regimens for this heavily treatment-experienced population.”
This continuous genotypic susceptibility score (cGSS) analysis, using the Stanford HIVdb (database), sought to understand the contribution of partially active ARVs on the durability of response to Trogarzo with optimized background regimens (OBRs). Trogarzo, combined with at least one fully functional ARV, remained effective across a range of cGSS scores through week 96, demonstrating its durability in treating multidrug-resistant (MDR) virus despite combination with compromised agents.
The second presentation highlights results from population PK modeling to simulate intramuscular (IM) and subcutaneous (SC) dosing based on seven past clinical studies with people living with HIV. The modelling was completed using IM and SC administration to deliver 400 mg weekly or 800 mg biweekly in 100 simulations. Both methods of administration maintained trough concentrations greater than 0.3 μg/mL, which has been previously correlated with efficacy. These data support the proof of concept that administration of Trogarzo via both IM and SC injection weekly or every two weeks are potential future improvements in convenience and accessibility. The PK and safety of Trogarzo IM administration are currently being evaluated in an open-label non-randomized phase 3 study.
The two scientific presentations show a combination activity between Trogarzo and nine other ARVs, seven commercially available and two investigational, demonstrating the additive or synergistic effects between each pairing. Of note, synergistic activities were seen with dolutegravir, etravirine, tenofovir alafenamide and lenacapavir, a long-acting investigational ARV.
Trogarzo is a long-acting CD4-directed post-attachment HIV-1 inhibitor. In combination with other antiretrovirals, it is used for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant (MDR) HIV-1 infection failing their current antiretroviral regimen.
Theratechnologies (TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs.
Theratechnologies (TH) is up today, trading at C$2.86 as of Jul 28, 2:34 p.m. EDT.